FluoGuide A/S Publishes Interim Report For Q4 2025

About this update from Fluoguide A/s

[{"type":"text","content":"COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report is available as attached document to this press release and on FluoGuide's website.","length":308,"tagName":"p"},{"type":"text","content":""In 2025, FluoGuide achieved several defining milestones that significantly advanced FG001 toward late-stage clinical development and established a clear regulatory pathway toward U.S. approval. The positive clinical data, strengthened organization, successful financing, and strategic collaboration with ZEISS collectively mark our transition from early clinical validation to execution toward registration and future commercialization. As we enter 2026, our focus is clear: advancing FG001 into registration studies and bringing innovative fluorescence-guided surgery closer to patients and surgeons worldwide." - Morten Albrechtsen, CEO of FluoGuide.","length":663,"tagName":"p"},{"type":"text","content":"Clinical progress strengthens FG001 foundationIn the fourth quarter, the Company reported positive interim results from an investigator-initiated FG001 trial in meningioma and low-grade glioma. The results were presented at EANS, CNS and EANO.","length":244,"tagName":"p"},{"type":"text","content":"Organization and leadershipDuring Q4 2025, FluoGuide strengthened its leadership organization to support clinical development and regulatory execution, including the appointment of a Chief Operating Officer and the election of a new Board member with experience in strategic business development.","length":297,"tagName":"p"},{"type":"text","content":"Strengthened financial position During the quarter, FluoGuide completed a directed share issue of SEK 104 million, securing funding to support the continued clinical development of FG001 and enabling progression toward late-stage clinical activities.","length":251,"tagName":"p"},{"type":"text","content":"Strategic collaboration with ZEISS In November 2025, FluoGuide entered into a collaboration agreement with ZEISS, a global leader in surgical microscopy. The collaboration supports the integration of FG001 within advanced surgical visualization workflows and represents an important step toward future clinical adoption.","length"...

More updates from Fluoguide A/s